US Pharma MarketingAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of Merck & Co.
Source: FierceBiotech